If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Until the second half of the 18th century, watches were luxury items; as an indication of how highly they were valued, English newspapers of the 18th century often include advertisements offering rewards of between one and five guineas merely for information that might lead to the recovery of stolen watches. By the end of the 18th century, however, watches (while still largely hand-made) were becoming more common; special cheap watches were made for sale to sailors, with crude but colorful paintings of maritime scenes on the dials. Up to the 1720s, almost all watch movements were based on the verge escapement, which had been developed for large public clocks in the 14th century. This type of escapement involved a high degree of friction and did not include any kind of jewelling to protect the contacting surfaces from wear. As a result, a verge watch could rarely achieve any high standard of accuracy. The first widely used improvement was the cylinder escapement, developed by the Abbé de Hautefeuille early in the 18th century and applied by the English maker George Graham. Then, towards the end of the 18th century, the lever escapement (invented by Thomas Mudge in 1755) was put into limited production by a handful of makers including Josiah Emery (a Swiss based in London) and Abraham-Louis Breguet. With this, a domestic watch could keep time to within a minute a day. Lever watches became common after about 1820, and this type is still used in most mechanical watches.
=== Allegations of patent infringement on mRNA technology (2022) === In August 2022, Moderna announced that it will sue Pfizer and its partner BioNTech for infringing its patent on the mRNA technology. In May 2024, the European Patent Office upheld the validity of Moderna's EP949 patent, one of the two patents asserted against Pfizer and BioNTech.
=== Cardiovascular effects === Dose-dependent changes of heart rate and cardiac output are observed within the first hour after administration of ractopamine and gradually return to baseline values. The systolic blood pressure will also increase in a dose-dependent manner, while the diastolic pressure remains unchanged.
=== 24 May === The governor of Russia's Belgorod Oblast said that a drone dropped an explosive device on a road in Belgorod city, damaging a car but leaving no casualties. During its annual assembly in Geneva, member states of the World Health Organization voted 80 votes to nine, with 52 abstentions, to condemn Russian aggression in Ukraine, including attacks on health care facilities, civilians and critical civilian infrastructure. All 27 EU members co-sponsored the move, with the exception of Hungary, which was absent from the vote. Besides Russia, the countries that voted against the draft resolution included China, North Korea, Syria, Belarus, Cuba and Algeria. The Russian Defence Ministry said the Ukrainian military launched an unsuccessful attack on the reconnaissance ship Ivan Khurs in the Black Sea using three unmanned speedboats. Video evidence the following day showed that one of the vessels had seemingly hit the Ivan Khurs. The Orthodox Church of Ukraine said it was switching to the new "Julian Calendar" from 1 September, in an effort to distance itself from the Russian Orthodox Church and citing Russian aggression. This was expected to lead to festivals like Christmas to be celebrated on 25 December instead of 7 January in Ukraine. The Russian Southern District Military Court in Rostov-on-Don said that five foreign nationals (Britons John Harding, Andrew Hill, and Dylan Heal, Swedish citizen Mathias Gustafsson, and Croatian national Vjekoslav Prebeg) were to be tried in absentia on 31 May for alleged terrorism and other charges.
Sources: en.wikipedia.org
== History == Polymers have been essential components of commodities since the early days of humankind. The use of wool (keratin), cotton and linen fibres (cellulose) for garments, paper reed (cellulose) for paper are just a few examples of how ancient societies exploited polymer-containing raw materials to obtain artefacts. The latex sap of "caoutchouc" trees (natural rubber) reached Europe in the 16th century from South America long after the Olmec, Maya and Aztec had started using it as a material to make balls, waterproof textiles and containers. The chemical manipulation of polymers dates back to the 19th century, although at the time the nature of these species was not understood. The behaviour of polymers was initially rationalised according to the theory proposed by Thomas Graham which considered them as colloidal aggregates of small molecules held together by unknown forces. Notwithstanding the lack of theoretical knowledge, the potential of polymers to provide innovative, accessible and cheap materials was immediately grasped. The work carried out by Braconnot, Parkes, Ludersdorf, Hayward and many others on the modification of natural polymers determined many significant advances in the field. Their contributions led to the discovery of materials such as celluloid, galalith, parkesine, rayon, vulcanised rubber and, later, Bakelite: all materials that quickly entered industrial manufacturing processes and reached households as garments components (e.g., fabrics, buttons), crockery and decorative items.
Pickled tofu (豆腐乳 in Chinese, pinyin: dòufurǔ, or 腐乳 fŭrŭ; chao in Vietnamese), also called "preserved tofu" or "fermented tofu", consists of cubes of dried tofu that have been allowed to fully air dry under hay and slowly ferment with the help of aerial bacteria. The dry fermented tofu is then soaked in salt water, Chinese rice wine, vinegar or minced chili peppers, or in a mixture of whole rice, bean paste, and soybeans. In the case of red pickled tofu (紅豆腐乳 in Chinese, Pinyin: hóng dòufurǔ), red yeast rice (cultivated with Monascus purpureus) is added for color. In Japan, pickled tofu with miso paste is called tofu no misodzuke, and is a traditional preserved food in Kumamoto. In the Ryukyu Islands, pickled and fermented tofu is called tōfuyō (豆腐餻). It is made from Shima-dōfu (an Okinawan variety of large and firm tofu). It is fermented and matured with koji mold, red koji mold, and awamori. Stinky tofu (臭豆腐 in Chinese, Pinyin: chòudòufu) is soft tofu that has been fermented in a vegetable and fish brine. The blocks of tofu have a pungent cheese smell, sometimes resembling rotting food. Despite its strong odor, the flavor and texture of stinky tofu is appreciated by aficionados, who describe it as delightful. The texture of this tofu is similar to the soft East Asian tofu from which it is made. The rind that stinky tofu develops when fried is said to be best when especially crisp, and fried stinky tofu is usually served with soy sauce, sweet sauce, or hot sauce.
== June 27, 1915 (Sunday) == Born: Grace Lee Boggs, American author and social activist, author of The Invading Socialist Society and The Next American Revolution; as Grace Chin Lee, in Providence, Rhode Island, United States (d. 2015)
topoisomerase Any of a class of DNA-binding enzymes which catalyze changes in the topological state of a double-stranded DNA molecule by nicking or cutting the sugar-phosphate backbone of one or both strands, relaxing the torsional stress inherent in the double helix and unwinding or untangling the paired strands before re-ligating the nicks. This process is usually necessary prior to replication and transcription. Topoisomerases thereby convert DNA between its relaxed and supercoiled, linked and unlinked, and knotted and unknotted forms without changing the sequence or overall chemical composition, such that the substrate and product molecules are structural isomers, differing only in their shape and their twisting, linking, and/or writhing numbers.
=== 2022 Mexican Open default === After a first-round doubles loss at the 2022 Mexican Open, Zverev repeatedly and violently struck umpire Alessandro Germani's chair with his racket, believing that Germani had incorrectly called a ball out during a tiebreak. Zverev was subsequently defaulted from the tournament, forfeiting all points and prize money that he had won thus far. He received the maximum fine of $40,000 by the ATP, an additional $25,000 fine, and a suspended eight-week ban. He was also placed on probation for one year. Zverev later issued an apology on social media.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.